Cheuk Hong Leung
Papers
2
Total Citations
113
H-Index
2
About
Dr. Cheuk Hong Leung is a leading clinical researcher in thoracic oncology, specializing in the surgical management of non–small cell lung cancer (NSCLC). His work centers on optimizing neoadjuvant immunotherapy strategies to improve outcomes for patients undergoing curative-intent surgery. Dr. Leung’s most influential study, published in 2022, demonstrated that neoadjuvant nivolumab, alone or combined with ipilimumab, yields high pathological response rates and manageable surgical safety in resectable NSCLC, garnering 94 citations for its pivotal impact on treatment paradigms. He further advanced this field in 2023 by comparing chemotherapy plus nivolumab against a triple regimen including ipilimumab, providing critical evidence on the balance between efficacy and surgical morbidity. These contributions have shaped how clinicians integrate immune checkpoint inhibitors before surgery, directly influencing patient selection and perioperative care. Dr. Leung’s research is widely cited for its rigorous methodology and real-world applicability, marking him as a key voice in the evolution of multimodal therapy for lung cancer. His work continues to guide surgeons and oncologists toward more personalized, immunologically-driven approaches.
Research Focus
Key Achievements
Top Papers
- 1
- 2